HomeCompareRGRX vs VIG

RGRX vs VIG: Dividend Comparison 2026

RGRX yields 666666.67% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RGRX wins by $8.275235618773884e+34M in total portfolio value
10 years
RGRX
RGRX
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full RGRX calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — RGRX vs VIG

📍 RGRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRGRXVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RGRX + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RGRX pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RGRX
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, RGRX beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RGRX + VIG for your $10,000?

RGRX: 50%VIG: 50%
100% VIG50/50100% RGRX
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RGRX buys
0
VIG buys
0
No recent congressional trades found for RGRX or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRGRXVIG
Forward yield666666.67%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.275235618773884e+34M$32.4K
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$179.15
Total dividends collected$8.275075881065991e+34M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: RGRX vs VIG ($10,000, DRIP)

YearRGRX PortfolioRGRX Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$66,677,367$66,666,666.67$11,304$163.92+$66.67MRGRX
2$415,506,651,117$415,435,306,334.37$12,759$166.33+$415506.64MRGRX
3$2,419,908,598,386,268$2,419,464,006,269,573.00$14,382$168.52+$2419908598.37MRGRX
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$16,192$170.52+$13171697643084.44MRGRX
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$18,210$172.34+$67004927492790120.00MRGRX
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$20,460$173.98+$318562277003514871808.00MRGRX
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$22,968$175.48+$1.415484168853553e+24MRGRX
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$25,763$176.83+$5.878130573362507e+27MRGRX
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$28,878$178.05+$2.2813793009840744e+31MRGRX
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$32,350$179.15+$8.275235618773884e+34MRGRX

RGRX vs VIG: Complete Analysis 2026

RGRXStock

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Full RGRX Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this RGRX vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RGRX vs SCHDRGRX vs JEPIRGRX vs ORGRX vs KORGRX vs MAINRGRX vs DGRORGRX vs NOBLRGRX vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.